Clostridium Difficile Infection Clinical Trial
Official title:
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection
Verified date | July 2023 |
Source | University of Wisconsin, Madison |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the efficacy of prophylaxis with oral vancomycin for preventing recurrent Clostridium difficile Infection (CDI) in patients who have experienced at least one CDI episode in the last 180 days and are receiving antibiotics for a non CDI condition. Participants will be randomized to receive either placebo or oral vancomycin in addition to their prescribed antibiotic therapy.
Status | Completed |
Enrollment | 77 |
Est. completion date | July 6, 2023 |
Est. primary completion date | July 6, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Willing to provide informed consent. - Willing to comply with all study procedures and be available for the duration of the study. - Documented diagnosis of at least one CDI within the last 180 days with treatment completed. - Currently receiving systemic antibiotics for a non-CDI condition with anticipated duration of no more than 2 weeks. - Females of childbearing potential must have a negative pregnancy test prior to randomization and agree to use adequate contraception prior to randomization, for the duration of the study, and for 4 weeks following study completion. - Have received no more than 72 hours of non-CDI antibiotics. Exclusion Criteria: - History of hypersensitivity or allergy to oral vancomycin. - Current use of oral vancomycin - Patients on concurrent treatment with metronidazole or tetracycline monotherapy for any indication - Patients diagnosed with inflammatory bowel disorder (Crohn's disease), or bacterial gastrointestinal infection cause by agents other than C. difficile (e.g. Salmonella sp.), toxic megacolon and/or known small bowel ileus. - Dysphagia (inability to swallow capsules) or unwilling to swallow capsules. - Major gastrointestinal surgery within 3 months of enrollment (does not include appendectomy or cholecystectomy). - Any history of total colectomy or bariatric surgery. - Unable or unwilling to fulfill study requirements. - Expected life expectancy < 6 months. - Patients enrolled in another clinical trial with investigational drugs within 30 days prior to randomization. - Women who are pregnant or breast-feeding. - Any patient deemed not suitable for study participation at the discretion of the study investigator. - Diarrhea (3 or more loose stools in a 24 hour period) at enrollment. |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin-Madison | Madison | Wisconsin |
United States | Medical College of Wisconsin | Milwaukee | Wisconsin |
Lead Sponsor | Collaborator |
---|---|
University of Wisconsin, Madison | Agency for Healthcare Research and Quality (AHRQ), Henry Ford Hospital, Mayo Clinic, Medical College of Wisconsin |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recurrent Clostridium difficile infection (CDI) | Determine whether CDI recurrence is decreased in patients taking oral vancomycin as prophylactic therapy in addition to standard-of-care antibiotics that patients are taking for non-CDI reasons. | 8 weeks | |
Secondary | Gut microbiome composition | Study how the gut microbiome is altered in patients receiving vancomycin treatment compared to placebo. | 8 weeks | |
Secondary | Vancomycin-resistant enterococcus (VRE) colonization in patients receiving vancomycin vs. placebo | Low-dose exposure to vancomycin and VRE infection has not been studied. We will examine the incidence of VRE colonization in all patients and determine whether oral vancomycin increases the VRE colonization rate. | 8 weeks | |
Secondary | Determine whether Clostridium difficile positivity on any stool sample is a predictor of CDI recurrence. | Stool samples will be tested at baseline, at the last dose date of vancomycin or placebo, at approximately 8 weeks following the last dose of vancomycin or placebo, and as indicated for diarrhea symptoms. Samples will be collected and tested for the presence of Clostridium difficile. | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02214771 -
Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients
|
N/A | |
Withdrawn |
NCT01552668 -
Fidaxomicin to Prevent Clostridium Difficile Colonization
|
Phase 4 | |
Recruiting |
NCT03325855 -
Fecal Microbiota Transplant National Registry
|
||
Not yet recruiting |
NCT03586206 -
Relationship Between C. Difficile Toxins' Serum Level With C. Difficile Infection
|
||
Suspended |
NCT03350711 -
A Screening and Recruitment Study in Adults Expressing Interest in the Emory Microbiota Enrichment Program
|
||
Withdrawn |
NCT03643887 -
Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients
|
Phase 2 | |
Terminated |
NCT04000555 -
Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI)
|
Phase 4 | |
Terminated |
NCT03065374 -
Treatment for Clostridium-difficile Infection With IMM529
|
Phase 1/Phase 2 | |
Completed |
NCT03710694 -
Safety and Efficacy of DAV132 in Patients at High-Risk for Clostridium Difficile Infection (CDI)
|
N/A | |
Completed |
NCT02865616 -
MET-2 Clinical Study for Recurrent Clostridium Difficile Infection (CDI)
|
Phase 1 | |
Recruiting |
NCT04940468 -
High- Fiber/ Low-fat Diet for Prevention of Recurrent Clostridioides Difficile Infection in Oncology
|
N/A | |
Completed |
NCT02589847 -
Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection
|
Phase 2 | |
Not yet recruiting |
NCT01942447 -
Fecal Microbiota Transplantation in Recurrent or Refractory Clostridium Difficile Colitis
|
N/A | |
Active, not recruiting |
NCT02086916 -
Novel Biomarkers to Predict Outcome in Clostridium Difficile Infection
|
N/A | |
Completed |
NCT01230957 -
Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults
|
Phase 2 | |
Completed |
NCT01241552 -
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)
|
Phase 3 | |
Not yet recruiting |
NCT04567134 -
Clostridioides Difficile Infection - a Prospective Nationwide Epidemiologic Study in Korea
|
||
Completed |
NCT04075422 -
Bezlotoxumab - in "Real Life" - During the First Episode of Clostridium Difficile Infection in Patients With High Risk of Recurrence.
|
||
Recruiting |
NCT03712722 -
Fecal Microbiota Transplantation (FMT) for Clostridium Difficile
|
||
Recruiting |
NCT05192148 -
Seroprevalence of Antibodies to Surface Antigens and Toxins of Clostridioides Difficile
|
N/A |